Treatment and outcomes of large vessel arteritis

被引:42
作者
Borg, Frances A. [1 ]
Dasgupta, Bhaskar [1 ]
机构
[1] Southend Univ Hosp, Dept Rheumatol, Westcliff On Sea SS0 0RY, Essex, England
来源
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY | 2009年 / 23卷 / 03期
关键词
giant cell arteritis; Takayasu's arteritis; visual loss; ischaemia; immunosuppression; GIANT-CELL ARTERITIS; CRANIAL ISCHEMIC COMPLICATIONS; POSITRON-EMISSION-TOMOGRAPHY; TAKAYASUS-ARTERITIS; DOUBLE-BLIND; POLYMYALGIA-RHEUMATICA; RISK-FACTORS; MYCOPHENOLATE-MOFETIL; VISUAL DETERIORATION; MONOCLONAL-ANTIBODY;
D O I
10.1016/j.berh.2009.04.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Giant cell arteritis (GCA) and Takayasu's arteritis (TA) are characterised by systemic inflammation and critical ischaemia. GCA is a medical emergency. Neuro-ophthalmic complications occur early, with permanent vision loss in up to a fifth of patients, resulting mainly from failure of prompt recognition and treatment. Diagnosis of large vessel vasculitis is often delayed due to poor recognition of early, often non-specific symptoms. Laboratory inflammatory markers are often discordant with disease activity. Modern imaging techniques show promise in diagnosis and disease monitoring, improving Our understanding of major artery involvement in large vessel vasculitis. However, in practice, their role is still unclear. The mainstay of therapy remains corticosteroids. Experience using conventional disease-modifying drugs is mixed, and biological therapies require further evaluation for their steroid-sparing potential. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:325 / 337
页数:13
相关论文
共 70 条
[1]   HOW DOES PREVIOUS CORTICOSTEROID TREATMENT AFFECT THE BIOPSY FINDINGS IN GIANT-CELL (TEMPORAL) ARTERITIS [J].
ACHKAR, AA ;
LIE, JT ;
HUNDER, GG ;
OFALLON, WM ;
GABRIEL, SE .
ANNALS OF INTERNAL MEDICINE, 1994, 120 (12) :987-992
[2]   Experience with infliximab (anti-TNFα monoclonal antibody) as monotherapy for giant cell arteritis [J].
Andonopoulos, AP ;
Meimaris, N ;
Daoussis, D ;
Bounas, A ;
Giannopoulos, G .
ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 (11) :1116-1116
[3]   Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis [J].
Bhatia, A ;
Ell, PJ ;
Edwards, JCW .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (07) :1099-1100
[4]   Mural inflammatory hyperenhancement in MRI of giant cell (temporal) arteritis resolves under corticosteroid treatment [J].
Bley, T. A. ;
Markl, M. ;
Schelp, M. ;
Uhl, M. ;
Frydrychowicz, A. ;
Vaith, P. ;
Peter, H. -H. ;
Langer, M. ;
Warnatz, K. .
RHEUMATOLOGY, 2008, 47 (01) :65-67
[5]   Diagnostic value of high-resolution MR imaging in giant cell arteritis [J].
Bley, T. A. ;
Uhl, M. ;
Carew, J. ;
Markl, M. ;
Schmidt, D. ;
Peter, H.-H. ;
Langer, M. ;
Wieben, O. .
AMERICAN JOURNAL OF NEURORADIOLOGY, 2007, 28 (09) :1722-1727
[6]   Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis:: A prospective study of 35 patients [J].
Blockmans, D ;
De Ceuninck, L ;
Vanderschueren, S ;
Knockaert, D ;
Mortelmans, L ;
Bobbaers, H .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2006, 55 (01) :131-137
[7]   Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis [J].
Boyev, LR ;
Miller, NR ;
Green, WR .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1999, 128 (02) :211-215
[8]   Utility values associated with blindness in an adult population [J].
Brown, MM ;
Brown, GC ;
Sharma, S ;
Kistler, J ;
Brown, H .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2001, 85 (03) :327-331
[9]  
Cantini F, 2001, ARTHRITIS RHEUM, V44, P2933, DOI 10.1002/1529-0131(200112)44:12<2933::AID-ART482>3.0.CO
[10]  
2-Y